ReviewCurrent cardiology reports2016
How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program.
Review in Current cardiology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Living with Transthyretin amyloid cardiomyopathy from a patient perspective.BMC cardiovascular disorders · 2025Article
- What services are currently provided to people with heart failure with preserved ejection fraction in the UK, and what are their components? A protocol for a scoping literature review.European journal of cardiovascular nursing · 2025Article
- Why We Should Care About Who Cares for Patients With Heart Failure With Preserved Ejection Fraction.Circulation. Heart failure · 2022Article
- Review
- A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction.ESC heart failure · 2021Observational
- Complex and Potentially Harmful Medication Patterns in Heart Failure with Preserved Ejection Fraction.The American journal of medicine · 2021Observational
- Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates.Clinical Medicine Insights. Cardiology · 2021Article
- Heart Failure with Preserved Ejection Fraction-a Concise Review.Current cardiology reports · 2020Review
- Management of heart failure with preserved ejection fraction.Australian prescriber · 2020Review
- Article
- 20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2019Article
- Preparation, optimization and in vitro-in vivo evaluation of Shunxin sustained release granules.Chinese medicine · 2019Article
- Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction.Clinical Medicine Insights. Cardiology · 2018Review
- Text Mining of the Electronic Health Record: An Information Extraction Approach for Automated Identification and Subphenotyping of HFpEF Patients for Clinical Trials.Journal of cardiovascular translational research · 2017Article
- Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.Journal of cardiovascular translational research · 2017Review
- Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.Journal of cardiovascular translational research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF), a highly prevalent and complex clinical syndrome with high morbidity and mortality, is often unrecognized and not optimally treated. Clinical trials for HFpEF have been plagued by low enrollment, and clinicians often approach HFpEF patients with "therapeutic nihilism" given the perceived lack of available therapies based on the disappointing results of these prior trials. Due to these challenges, we have pioneered the successful creation of dedicated, specialized HFpEF clinical programs. Here, we discuss (1) the rationale for the development of a specialized HFpEF clinical program; (2) strategies for the systematic identification of HFpEF patients; (3) a standardized diagnostic and therapeutic approach; (4) validation of the HFpEF clinical program paradigm; (5) staffing and reimbursement considerations; (6) HFpEF clinical trial enrollment; and (7) challenges and future directions for HFpEF clinical programs. We conclude that it is feasible to create HFpEF clinical programs that fulfill the major unmet need of identifying and caring for patients with HFpEF. These clinics are essential for confirming the HFpEF diagnosis, providing standardized treatment, and facilitating clinical trial enrollment. It is our hope that the information provided here will encourage others to establish their own specialized HFpEF programs, thereby allowing for comprehensive care for these complex patients.
Indexed as
Identifiers
27796858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.